Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System
Pediatric Blood & Cancer2006Vol. 48(4), pp. 447–452
Citations Over TimeTop 11% of 2006 papers
Wolfgang Stöhr, Marios Paulides, Stefan Bielack, H. Jürgens, J. Treuner, R. Rossi, Thorsten Langer, Jörn D. Beck
Abstract
Ifosfamide-induced nephrotoxicity was found in 4.6% of patients. Risk factors were the cumulative ifosfamide dose and young age at treatment.
Related Papers
- → Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System(2006)113 cited
- → A phase I–II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma(1988)40 cited
- → Yield of diagnostic tests in unexplained renal hypophosphatemia: a case series(2018)5 cited
- → 67P Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced soft tissue sarcoma: A single-arm phase II trial(2021)2 cited
- → Single-Agent Doxorubicin versus Doxorubicin Plus Ifosfamide in Advanced Soft Tissue Sarcoma(2012)